Clinical Trial Update: A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

A Phase 2 window-of-opportunity trial of Afatinib in early-stage non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gilotrif (Afatinib)

Snippet

Sponsor: Medical University of South Carolina | Conditions: Lung Cancer | Phase 2 | Status: WITHDRAWN